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Background: Hypoxia in utero can lead to stillbirth and severe perinatal injury. While current prenatal tests can
identify fetuses that are hypoxic, none can determine the severity of hypoxia/acidemia. We hypothesized a hypoxic/
acidemic fetus would up-regulate and release hypoxia-induced mRNA from the fetoplacental unit into the maternal
circulation, where they can be sampled and quantified. Furthermore, we hypothesized the abundance of hypoxia
induced mRNA in the maternal circulation would correlate with severity of fetal hypoxia/acidemia in utero. We
therefore examined whether abundance of hypoxia-induced mRNA in the maternal circulation correlates with the
degree of fetal hypoxia in utero.
Methods: We performed a prospective study of two cohorts: 1) longitudinal study of pregnant women undergoing
an induction of labor (labor induces acute fetal hypoxia) and 2) pregnancies complicated by severe preterm growth
restriction (chronic fetal hypoxia). For each cohort, we correlated hypoxia induced mRNA in the maternal blood
with degree of fetal hypoxia during its final moments in utero, evidenced by umbilical artery pH or lactate levels
obtained at birth. Gestational tissues and maternal bloods were sampled and mRNAs quantified by microarray
and RT-PCR.
Results: Hypoxia-induced mRNAs in maternal blood rose across labor, an event that induces acute fetal hypoxia.
They exhibited a precipitous increase across the second stage of labor, a particularly hypoxic event. Importantly, a
hypoxia gene score (sum of the relative expression of four hypoxia-induced genes) strongly correlated with fetal
acidemia at birth. Hypoxia-induced mRNAs were also increased in the blood of women carrying severely growth
restricted preterm fetuses, a condition of chronic fetal hypoxia. The hypoxia gene score correlated with the severity
of ultrasound Doppler velocimetry abnormalities in fetal vessels. Importantly, the hypoxia gene score (derived from
mRNA abundance in maternal blood) was significantly correlated with the degree of fetal acidemia at birth in this
growth restriction cohort.
Conclusions: Abundance of mRNAs coding hypoxia-induced genes circulating in maternal blood strongly correlates
with degree of fetal hypoxia/acidemia. Measuring hypoxia-induced mRNA in maternal blood may form the basis of
a novel non-invasive test to clinically determine the degree of fetal hypoxia/acidemia while in utero.
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Significant fetal hypoxia causing injury or death can
occur acutely, such as during labor [1], or it can occur
chronically as a result of poor placental function (pla-
cental insufficiency). Chronic hypoxia arising from pla-
cental insufficiency can also cause severe fetal growth
restriction (FGR).
When FGR occurs at significantly preterm gestations,
the risks of stillbirth are high and clinicians must judge
the optimal time to deliver the fetus. They are required
to balance the probability of stillbirth, neonatal death or
permanent disability (caused by severe fetal acidemia) if
the pregnancy is left to continue versus the risks of iat-
rogenic prematurity if the preterm fetus is delivered
unnecessarily early in gestation [2]. To help make these
decisions, tests of fetal well-being are used to determine
the likelihood that the fetus is significantly hypoxic.
These include the cardiotocograph (reports fetal heart
rate patterns) [3], biophysical profile (reports the pre-
sence/absence of fetal movement, breathing, tone and
amniotic fluid volume on ultrasound) [4] and Doppler
waveform velocimetry analysis of fetal vessels [5]. While
access to these tests has improved perinatal outcomes,
FGR fetuses are still lost to stillbirth or neonatal demise
or they suffer significant perinatal injury [6]. In a large
study of 604 live-born cases of preterm FGR (<33 weeks
gestation), major morbidity occurred in 35.9% of cases
and mortality was 21.5% [7]. As such, there is scope for
significant improvements in clinical outcomes.
A potential limitation of existing tests is that they
observe fetal physiological responses to hypoxia [8]. As
such, significant heterogeneity may be expected, where
the threshold of hypoxia/acidemia required to provoke
specific physiological responses captured by these tests
will vary between fetuses. In addition, current tests only
provide a likelihood that significant hypoxia is likely to
be present. Importantly, none are validated to provide a
quantitative estimate of the fetal blood pH/lactate con-
centrations (fetal acidemia). An approach measuring
fetal hypoxia at a biochemical/molecular level may be a
more direct strategy to determine the degree of fetal
hypoxia/acidemia in utero.
The discovery that fetoplacentally derived mRNA is
constantly released into the maternal blood from early
pregnancy until delivery raises the possibility of a new
way to monitor for the presence of fetal hypoxia/acide-
mia [9,10]. We hypothesized a hypoxic fetus would
up-regulate and release hypoxia-induced mRNA into
maternal blood. Furthermore, the relative abundance of
such transcripts may quantitatively correlate with the
degree of fetal acidemia. Thus, measuring hypoxia-
induced mRNA abundance in the maternal circulation
might form the basis of a non-invasive test to estimate
in utero fetal blood pH concentrations. We thereforeinvestigated whether hypoxia-induced mRNA abundance
in maternal blood correlated with the degree of fetal
hypoxia/acidemia in utero.
Methods
Study participants and specimens
Participants were recruited from two tertiary hospitals in
Melbourne (Monash Medical Centre and Mercy Hospital
for Women). We obtained approval from The Mercy Hos-
pital for Women Human Research Ethics Committee
(MHW R10/02) and The Southern Health Research Ethics
Committee B (MMC 09154B). All women provided writ-
ten informed consent.
To examine acute hypoxia, a prospective study was
undertaken in the birth suite. Maternal whole blood was
collected from women undergoing induction of labor at
term. An intravenous cannula was inserted at recruit-
ment reserved for sample collection for the study. Serial
blood samples were collected: prior to induction and
commencement of uterine contractions; at commence-
ment of the second stage of labor (full dilatation) and at
delivery. Fetal umbilical artery blood samples and pla-
cental biopsies were collected immediately after delivery.
Fetal hypoxic/acidemic status was determined by meas-
uring umbilical artery blood lactate levels. Thirty women
with documented fetal umbilical artery blood lactate
levels at delivery and complete sampling were matched
according to gestation, parity and maternal characte-
ristics to identify a normoxic (fetal umbilical cord lac-
tate <6 mmol/L) and hypoxic cohort (fetal umbilical
lactate >6 mmol/L).
To examine chronic hypoxia, serial maternal whole
blood samples were collected from 20 women carrying
severely growth restricted preterm fetuses and 30
controls. Severe FGR was defined as a customized
birthweight <10th centile (www.gestation.net, Australian
parameters) requiring iatrogenic delivery prior to 34 weeks’
gestation with uteroplacental insufficiency (asymmetrical
growth + abnormal umbilical artery Doppler velocimetry
+/- oligo-hydramnios). Women with superimposed pre-
eclampsia were included. Control blood samples (n = 30)
were collected from women carrying an appropriately
grown fetus (matched for gestation, parity and maternal
characteristics) and subsequently delivered at term without
complications.
Preterm placental samples (n = 8) were collected from
women delivering preterm an appropriate grown fetus
without hypertensive disease or histological evidence of
chorioamnionitis. We only included those in the FGR
cohort who delivered by caesarean to avoid the potential
bias caused by acute hypoxia of labor. For the FGR
cohort, fetal hypoxic status at delivery was determined
by measuring fetal blood pH levels obtained from the
umbilical artery at birth.
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A total of 2.5 mls of either maternal peripheral whole
blood and/or fetal umbilical cord blood samples were
collected in PAXgene whole blood RNA tubes (Pre-
Analytix, Hombrechtikon, Switzerland). According to the
manufacturer’s instructions, they were stored at room
temperature for 24 hours, then at -80C until processing.
Placental biopsies were obtained immediately after
delivery from the maternal side of the placenta avoiding
the decidua and fetal membranes (placental samples
from the FGR cohort were all after caesarean section).
Biopsies were washed in sterile phosphate buffered
saline, snap frozen and stored at -80°C until processing.
RNA preparation
Total RNA was extracted using the Paxgene miRNA sys-
tem (PreAnalytix/BD) according to the manufacturer’s
instructions. Total RNA was extracted from placental
tissue using the mirVana isolation kit (Ambion, Austin,
TX, USA) according to the manufacturer’s instructions.
Genomic DNA was removed using DNAse treatment.
RNA concentration and purity was measured using a
NanoDrop ND100 spectrophotometer (Thermo Scien-
tific, Pittsburgh, PA, USA). Microarray sample quality
were evaluated further by the BioAnalyser 2100 system
(Agilent, Santa Clara, CA, USA).
Microarray analyses
RNA samples were hybridized to Illumina Human Ref-8
Expression Beadchips for the labor ward study and the
Illumina HumanHT-12 Expression Beadchips (Illumina
Inc., San Diego, CA, USA) for the FGR study. Beadchip
processing was performed by the Australian Genome
Research Facility (Melbourne, VIC, Australia) according
to the manufacturer’s instructions. Scanned images were
analyzed using Illumina GenomeStudio. Gene expression
analysis was performed using BioConductor in R (www.
r-project.org) after quality control, preprocessing, back-
ground subtraction and normalization was performed.
Linear modeling was performed using the Limma pack-
age (www.bioinf.wehi.edu.au/limma/) and fold change
calculated using the t-test adjusted for multiple compari-
sons using the Benjamini and Hochberg methodology
for false discovery rate. Unsupervised hierarchical clus-
tering and principal component analysis were performed
to illustrate how well the patient groups could be sepa-
rated on the basis of the different molecular signatures.
GSEA software (www.broadinstitute.org/gsea) was used
to investigate over-representation of biological pathways,
comparing published biological pathways and the gene-
set developed in this study.
Microarray data are available in the ArrayExpress data-
base (www.ebi.ac.uk/arrayexpress) under accession num-
ber E-MTAB-2054.Validation with quantitative real-time reverse-
transcription polymerase chain reaction analysis
Real-time reverse-transcription polymerase chain reac-
tion (RT-PCR) validation of the 48 gene molecular signa-
ture was performed using the Taqman Hypoxia TLDA
(Applied Biosystems, Carlsbad, CA, USA) and specific
Taqman primers and probes for the candidate four gene
signature (Applied Biosystems). Reverse transcription of
200 ng of total RNA was performed using Superscript
Vilo or Superscript III (Invitrogen, Carlsbad, CA, USA).
All RT-PCRs were performed in triplicate using multiple
negative controls including RT and no-template controls.
We chose the combined expression of Gapdh, B2m and
Gusb as our internal control having validated that their
expression was not altered by hypoxia in these sam-
ples. The comparative CT method was used to de-
termine relative expression. Non-parametric statistical
tests were used for comparison of gene expression and the
Bonferroni correction for multiple comparisons was used
where appropriate.
Results
Expression of hypoxia-induced mRNA in fetal blood and
placenta sampled from fetuses acutely hypoxic during
labor
During labor, each uterine contraction abrogates ma-
ternal blood flow within the myometrium, decreasing
placental oxygenation [1]. Fetuses are rendered progres-
sively hypoxic as labor advances [1]. Therefore, labor is
effectively an in vivo functional ‘model’ of acute human
fetal hypoxia.
We first examined whether hypoxia-induced mRNA
transcripts are increased in gestational tissues (fetal
blood and placenta) in the presence of acute fetal hy-
poxia caused by labor. Blood lactate concentrations in
the umbilical artery (from the placenta) at birth are mea-
sured by clinicians to retrospectively determine whether
the fetus was genuinely hypoxic during its final mo-
ments in utero, where levels >6 mmol/L are consid-
ered elevated [11]. Therefore, we grouped our cohort
according to whether umbilical artery lactate concen-
trations were high (>6 mmol/L; hypoxia cohort) or
not (<6 mmol/L; controls).
Microarray and geneset enrichment analysis on mRNA
in fetal blood obtained from the umbilical artery at birth
revealed significant over-representation of hypoxia-
associated pathways in the hypoxia cohort. There was
global up-regulation of 41 hypoxia-induced transcripts
selected from the microarray in the hypoxia cohort
compared to controls (Figure 1A). PCR confirmed up-
regulation of four hypoxia-induced transcripts in the
fetal blood among the hypoxia cohort compared to con-
trols: hypoxia inducible factor 1α (Hif1α), Hif2α, adre-
nomedullin (Adm) and lactate dehydrogenase A (LdhA;






Figure 1 Expression of hypoxia-induced mRNA in gestational tissues obtained after labour. (A) Cluster analysis and a heatmap of 41
hypoxia induced genes in blood of fetuses from the hypoxia cohort (where umbilical artery lactate concentrations sampled from the placenta
soon after birth were >6.0 mmol/L) or controls (umbilical artery lactate <6.0 mmol/L). Green indicates increased expression, red is decreased
expression. Expression of hypoxia inducible factor (Hif)1α, Hif2α, adrenomedullin (Adm) and lactate dehydrogenase A ((LdhA) in (B) fetal blood and
(C) placenta obtained from the hypoxia cohort (n = 4) or controls (n = 4). Mean and S.E.M. are graphed. *P <0.05.
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centas from the hypoxia cohort compared to controls
(Figure 1C). Thus, hypoxia-induced mRNAs increase in
gestational tissues with fetal hypoxia.
Expression of hypoxia-induced mRNA in maternal blood
sampled at the moment of delivery in cases where the
fetus was significantly hypoxic at birth
Next, we investigated whether hypoxia-induced tran-
scripts were increased in maternal blood sampled at
the moment of birth, comparing the hypoxic cohort
(umbilical artery lactate concentrations >6 mmol/L)
with controls. We performed a prospective labor ward
study, recruiting women undergoing an induction of
labor. We placed a second intravenous cannula reserved
for collecting samples for the study (Additional file 1:
Table S1 lists clinical details). The ‘moment of birth’ sam-
ple was taken when the head was on view at the perineum
(vaginal opening) and delivery was imminent.Genomewide microarray and geneset enrichment ana-
lysis of mRNA isolated from maternal blood samples
taken at the moment of birth showed over-represen-
tation of hypoxia pathways in the hypoxia cohort (not
shown). Expression of 41 hypoxia-induced mRNA
selected from the array were globally increased in the
hypoxia cohort (Figure 2A). Samples grouped according
to fetal hypoxic status when unsupervised hierarchical
clustering was performed on the 41 genes subset. PCR
confirmed Hif1α, Hif2α, Adm and LdhA were up-
regulated in the hypoxia cohort (Figure 2B). Therefore,
trends seen in maternal blood (Figure 2A, B) mirrored
those seen in gestational tissues (Figure 1A-C).
Expression of hypoxia-induced mRNA in maternal blood
sampled longitudinally across labor
We next investigated whether hypoxia-induced tran-
scripts in maternal blood acutely increase within hours





Figure 2 Expression of hypoxia-induced mRNA in maternal blood from women in labor. (A) Cluster analysis and heatmap of 41 hypoxia
induced transcripts in maternal blood sampled moments before delivery from the hypoxia cohort (umbilical artery lactate concentrations
sampled at birth were >6.0 mmol/L) or controls (umbilical artery lactate <6.0 mmol/L). Green indicates increased expression, red is decreased
expression. (B) Hypoxia inducible factor (Hif)1α, Hif2α, adrenomedullin (Adm) and lactate dehydrogenase A (LdhA) expression in maternal blood
sampled moments before birth from the hypoxia cohort (n = 14) or controls (n = 16). Mean and S.E.M. are graphed. *P <0.05. **P <0.01.
***P <0.001.
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labor. A total of 22 of 44 hypoxia-induced transcripts
measured on a PCR array were significantly up-regulated
in maternal blood sampled at the moment of vaginal birth
compared to paired samples obtained prior to the onset of
labor (see Additional file 1: Table S2; Figure 3A graphs six
genes from the array). A further eight genes on the array
trended towards an increase (≥1.3-fold increase).
To exclude the possibility of a non-specific global rise
in mRNA transcripts in maternal blood across labor, we
assessed five transcripts coding growth-related genes by
PCR. None of these significantly increased across labor
(Additional file 1: Figure S1).
The second stage of labor (full cervical dilatation until
birth) is shorter in duration than the first stage (from
onset of contractions until full cervical dilatation), but
particularly hypoxic for fetuses where rapid decreases in
fetal arterial pO2, base excess and pH occur [1,12-14].
We measured Hif1α, Hif2α, Adm and LdhA expression
in maternal blood obtained from samples straddling the
first stage and second stage of labor (mean (± SD) 486
(± 242) minutes between sample collection) and com-
pared the relative increase to paired samples straddling
the second stage of labor (mean (± SD) 44 (± 55)
minutes between sample collection). There were only
minimal increases in gene expression across the first
stage of labor but far steeper increases across the second
stage (Figure 3B). Thus, hypoxia-induced transcripts do
not gradually increase across labor linearly with time
(this might be expected to occur if these transcripts were
released primarily in response to general inflammationthat occurs during labor [15] rather than fetal hypoxia).
Instead, they rose far more steeply during the much
shorter period of the second stage of labor. We suggest
the likely explanation is that fetuses are more hypoxic
during the second stage [1,12-14].
Correlation between hypoxia-induced mRNA in maternal
blood sampled at the moment of birth with fetal hypoxic
status at birth
We next examined whether hypoxia-induced transcripts
in maternal blood correlate with the degree of fetal hyp-
oxia/acidemia in utero. We developed a hypoxia gene ex-
pression score by summing relative expression of Hif1α,
Hif2α, Adm and LdhA in maternal blood obtained at the
moment of birth and correlating the scores with umbil-
ical artery lactate concentrations measured at delivery
(lactate concentrations in the umbilical artery positively
correlate with degree of in utero fetal acidemia around
the time of birth). There was a highly significant cor-
relation between the hypoxia gene expression score
and fetal blood lactate concentrations at delivery (Figure 4;
r = 0.81, P <0.0001). We conclude abundance of hypoxia-
induced transcripts in maternal blood correlates with the
fetal hypoxia/acidemia in utero in the setting of acute
hypoxia caused by labor.
Expression of hypoxia-induced mRNA in maternal blood
sampled from women with severe preterm growth
restricted fetuses
We next examined severe preterm fetal growth restric-
tion (FGR; n = 20, Table 1 shows the clinical details), a
Hif1α Hif2 Adm






Figure 3 Expression of hypoxia-induced mRNA in maternal blood from women sampled across labor. (A) Expression of six hypoxia-
induced transcripts in paired maternal blood sampled before labor was commenced and moments before delivery. Data were generated using a
Taqman PCR array. (B) Hypoxia inducible factor (Hif)1α, HIF2α, adrenomedullin (Adm) and lactate dehydrogenase A (LdhA) expression in serial samples
taken before labor was commenced (white bars; n = 30), during the second stage (full cervical dilatation) at either 120 to 180, 61 to 120 or 0 to
60 minutes prior to delivery (gray bars, sampling from the cohort of 30 were split among the three bars), and at the moment of birth (black bar;
n = 30). Thus, white and gray bars depict mRNA expression of genes in maternal blood at time-points straddling the beginning and end of the
first stage of labor (mean (± SD) 486 (± 242) minutes between sample collection), while the gray and black bars straddle the second stage of
labor (mean (± SD) 44 (± 55) minutes between sample collection). Data were generated using Taqman PCR. Mean and S.E.M. are graphed.
*P <0.05 **P <0.01 ***P <0.001.
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(n = 30) were uncomplicated pregnancies where ma-
ternal blood was obtained at the same gestational age
as the FGR cohort. Microarray and gene enrichment
analysis on mRNA isolated from maternal blood demon-
strated an over-representation of hypoxia pathways in theFGR cohort compared to controls. Samples clustered
according to whether fetuses were growth restricted or
not. There was global up-regulation of hypoxia-induced
mRNA in the FGR cohort (Figure 5A). PCR con-
firmed Hif1α, Hif2α, Adm and LdhA were significantly
up-regulated in the FGR cohort compared to controls
R = 0.81
Figure 4 Correlation between a gene hypoxia score and
umbilical artery lactate concentrations sampled after labour.
Gene hypoxia score is the sum of relative hypoxia inducible factor
(Hif)1α, Hif2α, adrenomedullin (Adm) and lactate dehydrogenase A
(LdhA) expression in maternal blood taken at the moment of
delivery. P <0.0001.
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obtained from FGR cases compared to two sets of con-
trols: gestation matched preterm placentas not compli-
cated by FGR and placentas obtained from healthy
pregnancies delivering at full term (Additional file 1:
Figure S2).Table 1 Patient characteristics for fetal growth restriction and
Maternal age (yrs)a
Parity (% primiparous)
Gestational age at delivery (weeks)a
Gestational age at sampling (weeks)a











Umbilical artery Doppler USS waveforms (%) REDFb
AEDFc
SDRd
FGR, fetal growth restriction; aMean (SD), bReversed End Diastolic Flow, cAbsent EndExpression of hypoxia induced mRNA in maternal blood
in the FGR cohort, split according to whether
preeclampsia was also present
To examine the possibility that co-existent preeclampsia
may affect expression of hypoxia-induced mRNA in ma-
ternal blood (and thus, be a confounder), we split our
FGR cohort according to whether there was concurrent
preeclampsia (n = 8) or not (n = 12). mRNA expression
of Hif1α, Hif2α, Adm and LdhA were all significantly
elevated in both FGR cohorts (that is, FGR with concur-
rent preeclampsia, and FGR without preeclampsia; see
Additional file 1: Figure S3) compared to gestationally-
matched controls (healthy pregnancies that progressed
to delivery at term of an infant with a normal birth
weight). Importantly, mRNA expression levels of all four
genes were no different between the FGR cohort with
concurrent preeclampsia and FGR without preeclampsia.
These data suggest mRNA coding hypoxia induced genes
are increased in the presence of severe FGR, irrespective
of the presence of preeclampsia.
Correlation between abundance of hypoxia-induced RNA
in maternal blood with severity of Doppler velocimetry
abnormalities
Ultrasound Doppler velocimetry of blood flow in the
umbilical artery is used clinically to serially monitor
hypoxic status of growth-restricted fetuses in utero [8].
A raised systolic-diastolic ratio (SDR) represents the
mildest abnormality, absent end diastolic flow (AEDF) iscontrol cohorts
FGR (n = 20) Control (n = 30) P =
30.4 (5.9) 29.5 (.8) 0.65
66 66 1.00
29 + 5 (21) 40 + 1 (10) <0.0001




885 (273) 3,403 (244) <0.0001
3 (3) 45 (16) <0.0001













Figure 5 Expression of hypoxia-induced mRNA in maternal blood from cases of severe fetal growth restriction (FGR). (A) Heatmap of 42
hypoxia induced genes in maternal blood sampled from controls and FGR cohort. Green indicates increased expression, red is decreased
expression. (B) Hypoxia inducible factor (HIF)1α, Hif2α, adrenomedullin (Adm) and lactate dehydrogenase A (LdhA) expression in maternal blood
sampled from controls (n = 30) and FGR cohort (n = 20). Mean and S.E.M. are graphed. **P <0.01 ****P <0.0001.
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fetal hypoxia [17] while reversed end diastolic flow
(REDF) has the strongest association with acidemia and
imminent fetal death. We measured Hif1α, Hif2α, Adm
and LdhA expression in maternal blood samples taken
in parallel with umbilical artery Doppler assessment and
confirmed a progressive increase with worsening Doppler
findings (Figure 6A).
Correlation between dynamic changes in hypoxia-
induced mRNA in maternal circulation and acute changes
in umbilical artery Doppler waveforms
Corticosteroids are often administered via intramuscular
injection to the mother to accelerate fetal lung matur-
ation, in preparation for preterm birth [18,19]. They can
induce acute, but transient improvements of the umbi-
lical artery Doppler waveforms over 24 to 72 hours (for
example, from AEDF to raised SDR) [20], while in some
cases, waveforms worsen [21]. Paired maternal blood
samples were taken just prior to, and 24 hours after,
corticosteroid administration. Decreased expression of
Hif1α (Figure 6B) was observed when the Doppler wave-
forms improved and conversely, increased expression of
Hif1α (Figure 6C) was observed when waveforms deteri-
orated after corticosteroid administration. This suggests
circulating hypoxia-induced transcripts in maternal blood
promptly change in parallel with very acute alterations in
presumed fetal hypoxic status.
Correlation between hypoxia-induced mRNA in maternal
blood sampled on the day of delivery with acidemic
status of FGR infants at the moment of birth
Lastly, we correlated the hypoxia gene expression score
(sum of the relative expression of Hif1α, Hif2α, Adm andLdhA) in maternal blood from samples taken on the day
of delivery with fetal acidemic status at birth (pH of fetal
blood drawn from the umbilical artery) in the FGR cohort.
We observed a strong correlation (Figure 7; r = 0.76,
P = 0.008) between the hypoxia gene score and umbilical
artery pH levels at birth (that is, fetal acidemic status,
where decreasing pH correlates with increasing fetal acid-
emia). In contrast, there did not appear to be an obvious
relationship between different severities of Doppler wave-
form velocimetry findings observed on the day of delivery
and final fetal acidemic status (Figure 7). We conclude the
hypoxia gene expression score correlates with fetal acide-
mic status in utero in FGR.
Discussion
Significant fetal acidemia at birth is strongly associated
with perinatal death and adverse perinatal complications,
including permanent neurological disability [6] and cere-
bral palsy [22]. In a study of 60 preterm fetuses delivered
at ≤28 weeks gestation, an umbilical artery blood pH
of ≤7.15 was strongly associated with severe adverse
neurological outcomes (sensitivity 30% at 98% specifi-
city) compared with higher pH levels [6]. In another
study of 604 neonates delivered at ≤33 weeks gestation,
an umbilical cord pH of ≤7.20 was associated with a 4.2
likelihood ratio of fetal death [7]. Therefore, a non-
invasive test that can estimate fetal acidemic status could
help clinicians’ better time delivery. While current non-
invasive antenatal tests can identify fetuses at higher risk
of being acidemic, none have been validated to accu-
rately estimate the degree of fetal acidemia in utero.
Here we have presented evidence to suggest quantify-
ing hypoxia-induced mRNA in the maternal circulation








Figure 6 Expression of hypoxia-induced mRNA in maternal blood in association with different umbilical artery velocimetry waveforms.
(A) Hypoxia inducible factor (HIF)1α, Hif2α, adrenomedullin (Adm) and lactate dehydrogenase A (LDHA) expression in maternal blood sampled
from women in the FGR cohort, grouped according to umbilical artery velocimetry waveform findings (SDR = Raised systolic/diastolic ratio;
AEDF = Absent end diastolic flow; REDF = Reversed end diastolic flow). AEDF and REDF results were compared with SDR findings. (B) Expression
of Hif1α in paired samples of maternal blood obtained around 24 hours apart from the FGR cohort, where umbilical artery velocimetry findings
either acutely improved (C) or worsened after administration of corticosteroids. Samples obtained at the time of the ultrasound examinations and
corticosteroids were given between the ultrasound examinations. Mean and S.E.M. are graphed. *P <0.05, **P <0.01.
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ternal circulation appear tightly correlated with expres-
sion in human gestational tissues, and they dynamically
change with acute alterations in presumed fetal hypoxic
status. Furthermore, we generated a hypoxia gene expres-
sion score that sums the relative abundance of mRNA in
the maternal circulation that code four hypoxia-induced
genes. This score appeared to be highly correlated
with acute (labor cohort) and chronic (FGR cohort) fetal
hypoxia.
While the measurement of free mRNA in the maternal
circulation has been studied previously, we believe our
study represents a significant conceptual advance. Previ-
ous studies have proposed the use of free mRNA as a‘static’ tool, where levels are measured once in order to
either diagnose [23,24] or predict pregnancy complica-
tions [25-27]. Here we propose serial measurements to
observe dynamic changes within the same patient, moni-
toring hypoxic status over time and delivering when sig-
nificant acidemia is predicted.
The cardiotocograph is the mainstay of monitoring to
identify hypoxia during labor. While it performs well in
identifying the presence of fetal hypoxia (85% sensitivity)
[1], its specificity is notoriously poor because heart rate
decelerations, including late decelerations, can either be
caused by hypoxia or be induced by mechanical reflex
autonomic responses unrelated to hypoxia. As a result,
use of the cardiotocograph results in unnecessary
R = 0.76
Figure 7 Correlation between a gene hypoxia score and
umbilical artery pH levels sampled at birth. Gene hypoxia score
is the sum of relative hypoxia inducible factor (Hif)1α, Hif2α,
adrenomedullin (Adm) and lactate dehydrogenase A (LdhA) expression
in maternal blood on the day of delivery. Samples were taken from
the fetal growth restriction cohort. P = 0.008. Colors indicate
umbilical artery waveform findings seen on the day of delivery:
Blue = Raised systolic/diastolic ratio, Green = Absent end diastolic
flow, Red = Reversed end diastolic flow.
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non-invasive test for women in labor that can determine
the degree of in utero fetal acidemia. The speed of
current PCR technologies means such a test is not feas-
ible as a clinical tool to make decisions during labor but
improvements in nucleic acid detection technologies
might make such a test possible in the future.
We have also presented evidence suggesting hypoxia-
induced mRNA in the maternal circulation correlates
with acidemic status of FGR fetuses’ in utero. It is con-
ceivable that day-to-day clinical decisions regarding tim-
ing of an FGR fetus can await the results of a PCR result
performed using machines available today. Therefore,
our test may have a role in situations where current tests
of fetal well-being are equivocal and the clinician is left
unsure whether the fetus should be delivered. This oc-
curs quite frequently. A prospective study examining a
preterm FGR cohort found biophysical profile results
were discordant with the umbilical artery Doppler find-
ings in 55% of cases [29]. Thus, a test that can provide a
reliable estimate of in utero fetal blood pH levels in such
situations may help clinicians decide whether immediate
delivery is warranted.
A limitation of our study is that we have not decisively
proven the hypoxia-induced mRNA we are measuring in
the maternal blood originates from the fetoplacental
unit. This may be possible with the use of next-
generation sequencing technologies where sequence
information could be used to identify the origin ofmRNA transcripts (maternal or fetal). However, we have
presented strong circumstantial evidence to suggest the
hypoxia induced mRNA are of fetoplacental origin: 1)
they increase with situations of likely severe acute and
chronic fetal hypoxia, 2) they correlate with an increase
of hypoxic mRNA transcripts in gestational tissues, and
3) their relative abundance displays a highly significant
and tight correlation with fetal acidemic status at birth.
Ultimately, if hypoxia-induced transcripts in maternal
blood were validated to reflect fetal acidemic status, it
would not be absolutely essential to establish their
origin, although a fetoplacental source seems the most
likely.
To translate our potential test to the monitoring of fe-
tuses with severe FGR, our test requires validation with
a study of larger numbers. Such a validation study could
also help determine whether clinical factors, such as
smoking and maternal obesity, alter hypoxia induced
mRNA levels in maternal blood. We are currently un-
dertaking such a large prospective validation study.
Furthermore, in this proof of concept study, we
summed the relative expression of mRNA in maternal
blood that codes Hif1α, Hif2α, LdhA and Adm to gene-
rate a gene hypoxia score. These genes were chosen on
the basis of their biology; the former three have central
roles in the hypoxic response [30], and Adm is both
hypoxic regulated [31] and very highly expressed in pla-
centa. Future studies should bioinformatically screen
other hypoxia-induced genes to develop the most accur-
ate test to determine degree of in utero fetal acidemia.
Finally, it may be more optimal to develop a clinical test
that expresses mRNA abundance by copy number rather
than relative expression.
In conclusion, we have presented evidence to show
measuring circulating hypoxia-induced transcripts in
maternal blood may be a promising approach to clinic-
ally assess fetal hypoxic status in utero. It may be useful
to help clinicians’ time delivery, especially in cases of
severe preterm FGR, potentially improving perinatal
outcomes and decreasing rates of stillbirth.
Conclusions
Abundance of mRNAs coding hypoxia-induced genes
circulating in maternal blood strongly correlates with
the degree of fetal hypoxia/acidemia, and they dynami-
cally change with acute alterations in presumed fetal
hypoxic status. Furthermore, a hypoxia gene expression
score that sums the relative abundance of mRNAs in the
maternal circulation was highly correlated with acute
(labor ward cohort) and chronic (FGR cohort) fetal hy-
poxia/acidemia. Therefore, measuring hypoxia-induced
mRNA in maternal blood may form the basis of a novel
non-invasive test to clinically determine the degree of
fetal hypoxia/acidemia while in utero.
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Additional file 1: Figure S1. mRNA of growth genes in maternal blood
across labor. Relative expression of mRNA coding five growth genes in
paired maternal blood obtained just before labour commenced and at
moment of delivery. GH: Growth Hormone; Adam12: Disintegrin and
metalloproteinase domain-containing protein 12; IGFR1: Insulin Growth
Factor 1 receptor; IGF: Insulin Growth Factor. Figure S2. Expression of
hypoxia-induced mRNA in placentas complicated by severe preterm fetal
growth restriction. Expression of five hypoxia induced mRNA in placental
specimens obtained from cases of preterm controls (no fetal growth
restriction, n = 8), term controls (delivered >37 weeks gestation, n = 8)
and severe preterm fetal growth restriction (FGR, delivered <34 weeks
gestation, n = 20). Comparisons were made between controls and the
FGR cohort. Hif: hypoxia inducible factor; Adm: adrenomedullin; LdhA:
lactate dehydrogenase A. *P < 0.05, **P < 0.01, ***P < 0.001. Figure S3.
mRNA in maternal blood among the FGR cohort, grouped according to
whether pre-eclampsia was present. Comparisons between fetal growth
restriction (FGR) with no pre-eclampsia (FGR - no PET; n = 12) versus FGR
with co-existent pre-eclampsia (FGR + PET; n = 8) were non-significant for
all four genes (P ≥ 0.41). Remaining comparisons, as shown in the graphs,
were made between both FGR groups and gestationally matched
controls (controls were pregnancies that progressed to delivery of an
infant of normal birthweight at term). Hif: hypoxia inducible factor; Adm:
adrenomedullin; LdhA: lactate dehydrogenase A. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. Table S1. Clinical characteristics for the
cohort who laboured. The group was stratified according to whether the
fetus was hypoxic (umbilical artery lactate concentrations >6.0 mmol/L)
or not (umbilical artery lactate concentrations <6.0 mmol/L) at birth.
Table S2. Expression of hypoxia-induced mRNAs in maternal blood
before labor compared to moment of birth.Abbreviations
Adm: Adrenomedullin; AEDF: Absent end diastolic flow; FGR: Fetal growth
restriction; Hif1α: Hypoxia inducible factor 1α; Hif2α: Hypoxia inducible factor
2α; LdhA: Lactate dehydrogenase A; mRNA: Message Ribonucleic acid;
PCR: Polymerase chain reaction; PET: Pre-eclampsia; REDF: Reversed end
diastolic flow; SDR: Raised systolic-diastolic ratio.Competing interests
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